Biogen Inc (NASDAQ:BIIB) price target set to $427.00 by Mizuho

ME Staff
-
0

Analyst Ratings For Biogen Inc (NASDAQ:BIIB)

Today, Mizuho set its price target on Biogen Inc (NASDAQ:BIIB) to $427.00 per share.

There are 20 Buy Ratings, 9 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Biogen Inc (NASDAQ:BIIB) is Buy with a consensus target price of $376.6722 per share, a potential 11.79% upside.

Some recent analyst ratings include

    Recent Insider Trading Activity For Biogen Inc (NASDAQ:BIIB)
    Biogen Inc (NASDAQ:BIIB) has insider ownership of 0.29% and institutional ownership of 87.35%.

    • On 4/25/2018 Alexander J Denner, Director, bought 48,000 with an average share price of $269.91 per share and the total transaction amounting to $12,955,680.00.
    • On 2/27/2018 Alfred Sandrock, EVP, sold 259 with an average share price of $290.83 per share and the total transaction amounting to $75,324.97.
    • On 2/20/2018 Alfred Sandrock, EVP, sold 743 with an average share price of $292.00 per share and the total transaction amounting to $216,956.00.
    • On 2/15/2018 Alfred Sandrock, EVP, sold 1,294 with an average share price of $298.85 per share and the total transaction amounting to $386,711.90.
    • On 1/9/2018 Robert W Pangia, Director, sold 5,832 with an average share price of $329.65 per share and the total transaction amounting to $1,922,518.80.
    • On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
    • On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.

    About Biogen Inc (NASDAQ:BIIB)
    Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

    Recent Trading Activity for Biogen Inc (NASDAQ:BIIB)
    Shares of Biogen Inc closed the previous trading session at 337,18 up +5,72 1,73 % with 562167 shares trading hands.